Antihepatic Fibrosis Drugs in Clinical Trials.
Antihepatic Fibrosis Drugs in Clinical Trials.
复制标题
DOI：
10.14218/jcth.2020.00023
复制
发表时间：
2020-09-28
影响因子：
3.6
通讯作者：
Lu LG
中科院分区：
文献类型：
--
作者：
Guo YC;Lu LG
肝纤维化不是一种独立的疾病。是指各种致病因素引起的肝脏结缔组织异常增生。到目前为止，肝纤维化已被认为与一系列因素有关，如病毒感染，酒精滥用，非酒精性脂肪肝疾病和自身免疫性肝炎以及遗传性疾病。迄今为止，肝纤维化的临床治疗仍然面临挑战，因为消除潜在原因和常规抗纤维化药物不能减轻大多数患者的纤维化。近年来，人们通过基础和临床研究探索了肝纤维化的潜在治疗靶点，如代谢、炎症、细胞死亡和细胞外基质。因此，在目前的临床试验中，对抗肝纤维化药物进行综述已迫在眉睫。
Liver fibrosis is not an independent disease. It refers to the abnormal proliferation of connective tissues in the liver caused by various pathogenic factors. Thus far, liver fibrosis has been considered to be associated with a set of factors, such as viral infection, alcohol abuse, non-alcoholic fatty liver disease, and autoimmune hepatitis, as well as genetic diseases. To date, clinical therapeutics for liver fibrosis still face challenges, as elimination of potential causes and conventional antifibrotic drugs cannot alleviate fibrosis in most patients. Recently, potential therapeutic targets of liver fibrosis, such as metabolism, inflammation, cell death and the extracellular matrix, have been explored through basic and clinical research. Therefore, it is extremely urgent to review the antihepatic fibrosis therapeutics for treatment of liver fibrosis in current clinical trials.